Considering that mycobacterial heat-shock protein 65 (hsp65) gene transfer can elicit a profound antitumoral effect, this study aimed to establish the safety, maximum-tolerated dose (MTD) and preliminary efficacy of DNA-hsp65 immunotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC). For this purpose, 21 patients with unresectable and recurrent HNSCC were studied. Each patient received three ultrasound-guided injections at 21-day intervals of: 150, 600 or 400 mg of DNA-hsp65. Toxicity was graded according to CTCAE directions. Tumor volume was measured before and after treatment using computed tomography scan. The evaluation included tumor mass variation, delayed-type hypersensitivity response and spontaneous peripheral blood mononuclear cell proliferation before and after treatment. The MTD was 400 mg per dose. DNAhsp65 immunotherapy was well tolerated with moderate pain, edema and infections as the most frequent adverse effects. None of the patients showed clinical or laboratory alterations compatible with autoimmune reactions. Partial response was observed in 4 out of 14 patients who completed treatment, 2 of which are still alive more than 3 years after the completion of the trial. Therefore, DNA-hsp65 immunotherapy is a feasible and safe approach at the dose of 400 mg per injection in patients with HNSCC refractory to standard treatment. Further studies in a larger number of patients are needed to confirm the efficacy of this novel strategy.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequent form of cancer worldwide.
1,2 It corresponds to 3% of all malignant cancers in the United States, but is much more prevalent in Brazil, where it accounts for 6% of all cancer deaths. 3 Although major advances in surgical, radiation and chemotherapeutic approaches have been made in the last 25 years, these efforts had no significant impact on the survival of patients with advanced HNSCC. 4, 5 Therefore, novel therapeutic strategies aiming at improving survival and quality of life are needed. Different treatment modalities are currently being tested in clinical trials, for example electrochemotherapy, 6 intra-arterial chemotherapy, 7 cytokine peritumoral injection, 8, 9 vaccines 10 and gene therapy. 11 Immunotherapy-the concept of boosting the immune system to target and destroy cancer cells-has been a goal in cancer treatment for over 100 years. However, limited success has been achieved with traditional immunotherapy, as cancer cells tend to evolve mechanisms to evade effector immune response. A wide array of gene therapy techniques are being used to overcome this limitation and the cancer vaccines based on heat-shock proteins (HSPs) are considered as a promising approach. [12] [13] [14] It has been demonstrated that purified preparations of Gp96, Hsp70, Hsp90 and certain other HSPs from normal or cancer cells are noncovalent associations between HSPs and peptides, known as-HSP-peptide complexes. [15] [16] [17] Likewise, the mycobacterial Hsp65 can also be associated with different peptides. 18 These HSP-peptide complexes are potent inducers of immunity 19, 20 and have been employed as vaccine adjuvants targeted to different cancers and infections. 21 In addition, HSPs can induce a polyclonal immune response and activate NK cells. 22, 23 Thus, HSPbased vaccines emerge as promising strategy for immunotherapy. Accordingly, vaccination with autologous tumor-derived HSP-peptide complexes has been shown to result in both prophylactic and therapeutic antitumoral activity in a variety of animal models of cancer and several advanced clinical studies using autologous tumorderived HSPs are underway. 21 Recently, two ongoing clinical trials using HSP-based vaccines in cancer have been registered at the NIH clinical trials site (http://www.clinicaltrials.gov/), but no results have yet been published.
Our group and others have previously shown the induction of a robust inflammatory immune response by vaccination with DNA-hsp65 in different animal models of infections and cancer. The use of the DNA-hsp65 vaccine showed an important prophylactic and therapeutic effect in vivo against tuberculosis. 24, 25 This vaccine also induced upregulation of MHC class I and class II molecules on macrophages. 26, 27 Moreover, different groups have found that mycobacterial hsp65 gene transfer can elicit a profound antitumoral effect. 28, 29 The transfection of J774 histiocytic sarcoma cells with the hsp65 gene resulted in reduced tumor development, and immunization with hsp65-transfected sarcoma cells in mice was protective against challenge with unmodified parental tumor cells. 28 Taken together, these data indicate the remarkable immunogenicity of Hsp65.
In contrast, a concern when dealing with HSPs-based vaccines is their potential to induce autoimmune disease, due to their high molecular conservation among species and crossreactivity with endogenous HSPs. However, preclinical data from our group and others using different animal models show no evidence of autoimmune disease when DNA-hsp65 was used for immunization. [24] [25] [26] 30 It is relevant to point that the immunogenicity of tumor-derived HSP-peptide complexes has been shown to be individually tumor specific and not tumor-type specific. This suggests that the relevant immunoprotective peptides are most likely derived from individual tumorspecific antigens rather than from shared tumor antigens. 19 This was the rationale behind the vaccination protocol used in the present study, in which each patient was vaccinated intratumorally with DNA-hsp65 favoring the formation of chaperone-peptide complexes between transfected Hsp65 and antigens of the patient's own tumor. Here, we have evaluated the feasibility, safety and preliminary efficacy of DNA-hsp65 immunotherapy in advanced HNSCC patients.
Patients and methods

Trial design
The study was designed as uncontrolled, nonrandomized, single-institution, open-label, dose escalation, phase I trial to test the safety and feasibility of DNA-hsp65 immunotherapy of patients with recurrent HNSCC. Three different doses of DNA were tested with six patients in each dose group (Figure 1 ).
Patient eligibility
Eligibility criteria included patients with unresectable locoregional HNSCC after standard therapies that necessarily included radiotherapy. Subjects were also required to have tumor lesions accessible for injection; histologically confirmed diagnosis of HNSCC; life expectancy X3 months; age X18 years; Karnofsky index 470%; no previous malignancies; adequate hematologic, renal and hepatic function; psychosocial status compatible with participation; and to have signed a term of free informed consent, according to Institutional and National Guidelines. Exclusion criteria included pregnancy, HIV infection, significant comorbidities (including coronary artery disease, symptomatic congestive heart failure, active alcohol abuse, diabetes and autoimmune diseases), other malignancies and chemotherapy, hormonal therapy, immunotherapy, biological therapy, surgery or radiotherapy within 4 Figure 1 Dose escalation schedule: 7 days before the beginning of the treatment a computed tomography scan (CT scan) for tumor estimation was performed. Three intratumoral doses of 'naked' DNAhsp65 were injected with ultrasonography guidance with 3 weeks intervals. Each dose was of 150 mg (Group A), 600 mg (Group B) and 400 mg (Group C). *Patients were followed up until death. Two patients are still alive 43 years after DNA therapy.
Research, School of Medicine of Ribeira˜o Preto, University of Sa˜o Paulo. The preparations were sterile, lacked detectable contamination with bacterial RNA and genomic DNA, and had protein and endotoxin levels in compliance with US and European pharmacopeias. 31 The product was supplied in ready-to-use 2-ml glass vials containing naked DNA-hsp65 as lyophilized powder, diluted with sterile water to obtain the desired concentration for intratumoral injection. A fixed volume of 1.5 ml was injected in one or two areas of the tumor depending on its' volume. On the basis of toxicological studies in rodents, the dose of 150 mg was selected as the starting dose for this trial. All patients followed the same treatment course and received intratumoral injections with their group dose (Group A 150 mg, Group B 600 mg and Group C 400 mg)-on days 0, 21 and 42 ( Figure 1 ). Enrollment proceeded to the next dose level after all patients in the previous dose group were treated for X30 days and safety data were reviewed. If no dose-limiting toxicity event occurred, the next dose level was opened. Intratumoral injection was guided by ultrasonography to avoid injection into vessels and necrotic areas. To prevent infections, injections were performed through the neck, whenever possible, even in the case of ulcerated tumors of the mouth.
Toxicity evaluation
Toxicity was graded according to version 3.0 of the US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Patients were evaluated for side effects related to the injections, including a complete clinical evaluation, electrocardiogram, chest X-ray, echocardiogram and standard blood tests including differential blood counts, serum chemistry, urinalysis, and cardiac, hepatic and renal functions. Clinical and laboratory examinations were carried out throughout the study to assess possible autoimmune reactions (rheumatic factor and antimicrosomal, antithyroglobulin and antinucleoprotein antibodies).
Measurement of tumor volume and potential predictors of immunostimulation
A computed tomography scan was performed less than 7 days before the first injection of DNA-hsp65 and at day 49 of treatment, when the last dose was given. All scans were performed using a Philips Medical Systems multislice machine, model IDT10 or IDT16 with 1.5-mm thick slices. Tumor volume was calculated using the Shaded Surface Display 3-D software (SSD-3D). The selection of tumor borders was performed manually on sequential axial images 2 mm thick. Volume was then automatically calculated by the software in mm 3 ( Figure 2 ). All scans and reconstructions were recorded. Response to treatment was considered in terms of variation in tumor volume according to the Response Evaluation Criteria in Solid Tumors (RECIST):
32 no evidence of disease was considered as a complete response; partial response applies to a greater than 30% decrease in tumor volume; stable disease corresponds to less than 30% decrease and less than 20% increase in tumor volume; and progression corresponds to greater than 20% increase in tumor volume. DNA-hsp65 vaccine in head and neck tumor therapy P Michaluart et al
Delayed-type hypersensitivity (DTH) skin tests were also performed for the evaluation of cellular immune response status before and after treatment. DTH was carried out by subcutaneous injection of 0.1/2 UT of purified protein derivative (PPD) RT23SSI (Stateus Serum Institute, Copenhagen, Denmark), and tricophytin and candidine (FDA Allergenic, Sa˜o Paulo, Brazil). In addition, both cellular and humoral immunity to Hsp65 were evaluated before and following treatment (Victora et al., 40 manuscript submitted for publication). In the present paper, we present data on the spontaneous proliferation of peripheral blood mononuclear cells (PBMCs) in the course of treatment. For this analysis, 10-40 ml of heparinized blood were obtained from patients whenever possible, before each dose of vaccine and at 3, 6 and 12 months after the initial dose. PBMCs were isolated by Ficoll-Hypaque gradient centrifugation, 2 Â 10 5 PBMCs were cultured in quadruplicate for 5 days in round-bottom 96-well plates. At the end of the fifth day, cells were incubated for 18 h with 2.5 mCi ml
Results
A total of 21 patients were enrolled in the study (Table 1) . Median age was 57.7 years (range: 33-73 years). Two of these patients had stage III disease and the remaining 19 had stage IV disease on the first presentation. Seventeen patients had previously undergone surgery, 9 had received at least one prior chemotherapy regimen, and all patients had been treated with radiotherapy ( Table 1) .
The most frequent adverse events were increased pain, edema and infections (Table 2) . Although all of these events may have been natural consequences of disease progression, we adopted a systematic approach considering them related to the treatment. According to this evaluation, the great majority of related adverse events were of minor intensity. Nonetheless, in Group B, two patients showed related edema (grades 3 and 4), and two other patients showed grade 4, possibly and probably related pain, the former accompanied by grade 4, possibly related edema. We, therefore, decided to downscale the original 1200 mg per dose intended for Group C to 400 mg per dose.
None of the patients showed either clinical or laboratory alterations compatible with autoimmune disease. However, on day 103, Patient no. 11, who had stable disease on day 49, presented an asymptomatic pericardial effusion diagnosed by echocardiogram, together with clinical progression of disease. We considered this pericardial effusion as a possibly related event (Tables 2 and 3 ). This patient responded to nutritional and clinical treatment but died on day 228 due to progression of disease with skull base involvement. Autopsy showed no evidence that the effusion was of autoimmune origin.
Only five patients were responsive to DTH tests prior to treatment and this was not correlated to clinical response (Table 3) . Two patients (Patient nos. 4 and 10) who tested negative before the beginning of the treatment became positive for PPD after vaccination. All but two DNA-hsp65 vaccine in head and neck tumor therapy P Michaluart et al patients showed at least one sign of immunostimulationincluding DTH, pain, edema and spontaneous PBMC proliferation-following vaccination (Table 3) .
Proliferation of PBMCs was analyzed in 11 vaccinated patients; however, only 8 patients could be evaluated before and after vaccination. Sample losses were substantial, mainly due to the poor health status of patients, which prevented the collection of the amount of blood originally intended, and to the lack of viability of some cell samples. At least a twofold increase in spontaneous proliferation was observed after vaccination in four out of eight patients evaluated before and after vaccination (Patient nos. 1, 6, 11 and 21) ( Table 3 and Figure 3 ). Spontaneous proliferation decreased after vaccination in one patient (Patient no. 20) (Table 3) .
Computed tomography scan with tumor volume measurement was performed in all patients before the first injection. Six patients died before the second scan, none of which due to causes considered as related to DNA-hsp65 vaccination. The most frequent causes of death were disease progression and fatal bleeding. Patient no. 20 was not examined due to technical difficulties (Table 3) .
Of the 14 patients whose tumor volume was measured before and after the treatment, 4 showed partial regression (Patient nos. 1, 3, 4 and 10), 1 showed stable disease (Patient no. 11) and 9 showed disease progression ( Table 3) (Table 3) .
Discussion
It is thought that cancer cells survive because they are not recognized by the immune system or fail to elicit an adequate immune response. Therefore, several 
Abbreviations: Gr, grade of the adverse event; hsp, heat-shock protein; PB, probably related and PS, possibly related to the treatment; R, related.
a The asymptomatic pericardial effusion was evidenced in Patient no. 11, on day 103 after the beginning of the therapy.
DNA-hsp65 vaccine in head and neck tumor therapy P Michaluart et al Abbreviations: DTH, delayed-type hypersensitivity; hsp, heat-shock protein; ND, not done; PBMC, peripheral blood mononuclear cell; PPD, tuberculin-purified protein derivative; Pre, pre-treatment; Post, post-treatment on day 49 of the schedule.
Patients who showed parameters of immunostimulation are indicated in gray lines. All patients showed pain and edema. immunotherapeutic approaches for cancer involve adding a molecular 'danger signal' to previously unrecognized or poorly recognized tumor antigens, thereby enhancing presentation of antigens to the immune system. 33 HSPs may well be used in such scenario because they are known to augment innate and antigen-specific effectors functions. 21 Here, we report the use of DNA-hsp65 vaccine in HNSCC patients. This is the first clinical trial using the hsp65 gene from mycobacterial origin, previously shown by different groups to be efficient against tuberculosis and in preventing and reducing tumor growth in preclinical models. [24] [25] [26] 28, 30, 34, 35 We have had the care to create GMP conditions in our laboratory exclusively to produce DNA-hsp65 vaccine for clinical use. The vaccine injections were ultrasound guided, which guaranteed the injection in solid parts of the tumor, avoiding necrotic areas and vessels. This could give our protocol two additional advantages. First, it enhanced the possibility of transfection of tumor cells with DNA-hsp65, thus increasing the repertoire of peptide-complexed antigens. This approach was considered to be particularly promising for tumors in which dominant antigens are poorly characterized as is the case of HNSCC. Second, considering that Hsp65 is an immunodominant antigen in mycobacteria, 36 the expression of this foreign protein by tumor cells in the context of HLA class I molecules could lead to breakdown of the tolerogenic environment found in cancer patients.
As with any new type of therapy, there are important safety concerns. Newer and safer gene delivery agents have been created and thousands of cancer patients worldwide either have participated or are currently enrolled in gene therapy trials, with remarkably few treatment side effects. 37 There are often localized swelling and inflammation at the site of the injection. 38 However, when compared with the side effects of conventional chemotherapeutic treatments, these side effects are minimal. In our study, the most important adverse events, namely pain and edema, were locoregional and could be the result of local inflammation induced by the intratumoral naked DNA injection or correspond to the immune response elicited against the tumor. Interestingly, toxicity seemed to be dose dependent, but clinical response was not.
Tumor volume is an important parameter for assessing therapeutic results. The traditional assessment of tumor size, measuring the two greatest diameters of the tumor, is not accurate for the cases in the present study, which have recurrent, often ulcerated lesions with irregular limits. Although more complex, the method used here allowed a more reliable measurement of tumor volume. Despite the fact that two patients with initial tumor volumes smaller than 10 mm 3 showed disease progression, the two patients who best responded to treatment, and who are still alive 3 years after completion of the trial, had small tumors to start with. This is particularly important considering the type of tumor and the type of immunotherapy tested in the present trial, which consisted of naked DNA encoding a single gene. This contrasts with other therapeutic trials reported in the literature, in which mixed plasmid constructions at higher doses and with adenoviral or cytokine boosters were tested. 39 Another concern is that patients in this trial may not be immunocompetent enough to respond to the DNA-hsp65 stimulus. Interestingly, all four patients who showed reductions in tumor volume were DTH-negative prior to vaccination. However, these patients showed at least one sign of immunostimulation-including DTH, pain, edema and spontaneous PBMC proliferation after immunizations. In contrast, none of the five patients initially DTH responders, showed favorable clinical outcome.
Immunological evaluation of patients in this clinical trial included humoral response to mycobacterial Hsp65 and human Hsp60, antigen-specific proliferation and both IFN-g and IL-10 production by ELISPOT. These data are presented in a separate paper (Victora et al., 40 manuscript submitted for publication). It is relevant to point out in the present report that almost all patients (19 out of 21) showed signs of immune stimulation and 4 patients also showed a decrease in tumor size, suggesting that the vaccine was able to interfere with the immunological status of patients. Moreover, in four patients, spontaneous PBMC proliferation increased after vaccination, and in two patients a progressive increase was detected during the course of treatment.
In summary, considering the type of tumor and the therapy tested, our data indicate that vaccination with DNA-hsp65 is a feasible and safe approach. Moreover, the clinical benefit observed in a limited number of patients who responded to the vaccine and the urgent need for new therapeutic resources for advanced HNSCC patients warrant further confirmatory studies designed to evaluate clinical and immunological outcomes in a larger number of patients.
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